AtriCure Inc
$ 31.14
-2.04%
24 Feb - close price
- Market Cap 1,580,503,000 USD
- Current Price $ 31.14
- High / Low $ 32.69 / 30.80
- Stock P/E N/A
- Book Value 9.88
- EPS -0.61
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE -0.02 %
- 52 Week High 43.18
- 52 Week Low 28.29
About
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.
Analyst Target Price
$49.38
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-10-29 | 2025-07-28 | 2025-04-29 | 2025-02-13 | 2024-10-29 | 2024-07-30 | 2024-05-01 | 2024-02-15 | 2023-11-01 | 2023-07-25 | 2023-05-02 |
| Reported EPS | 0.06 | -0.01 | -0.02 | -0.14 | -0.08 | -0.17 | -0.17 | -0.28 | -0.21 | -0.2 | -0.11 | -0.23 |
| Estimated EPS | -0.0991 | -0.11 | -0.167 | -0.2234 | -0.1488 | -0.19 | -0.17 | -0.23 | -0.23 | -0.31 | -0.3 | -0.34 |
| Surprise | 0.1591 | 0.1 | 0.147 | 0.0834 | 0.0688 | 0.02 | 0 | -0.05 | 0.02 | 0.11 | 0.19 | 0.11 |
| Surprise Percentage | 160.5449% | 90.9091% | 88.024% | 37.3321% | 46.2366% | 10.5263% | 0% | -21.7391% | 8.6957% | 35.4839% | 63.3333% | 32.3529% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.0991 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATRC
2026-02-24 06:51:31
AtriCure (ATRC) recently announced improved 2025 results and positive 2026 guidance, projecting $600-$610 million in revenue and positive net income, despite recent share price declines. While a narrative valuation suggests the stock is 39.8% undervalued at $31.79 against a fair value of $52.78, a Discounted Cash Flow model indicates a fair value of only $0.86, presenting conflicting signals for investors. The company's ongoing clinical trials, LeAAPS and BoxX-NoAF, are expected to expand its market if successful outcomes lead to broader indications for stroke prevention and preventative cardiac surgery.
2026-02-23 08:04:00
This article provides a price-driven insight into Atricure Inc. (NASDAQ: ATRC) for rule-based strategies, highlighting divergent sentiment across all horizons and elevated downside risk. It presents three AI-generated institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis. The piece also promotes access to real-time signals and personalized dashboard features for subscribers.
2026-02-20 12:52:24
Zacks Research downgraded AtriCure (ATRC) to "hold" from "strong-buy" despite the company beating Q4 EPS expectations with 13.1% year-over-year revenue growth. The stock currently holds a "Moderate Buy" consensus rating among analysts with an average price target of $48.43, but faces concerns over negative net margin and P/E, and projected negative EPS for the current year. Insider selling has also been noted, with 15,166 shares offloaded in the past three months.
2026-02-19 17:26:44
AtriCure, Inc. has released its 2025 Form 10-K report, showcasing significant financial improvements and strategic advancements in a competitive industry. The company reported increased revenue, improved gross profit, and a reduced net loss, driven by growth in its open ablation, appendage management, and pain management product lines. AtriCure is also focused on product innovation, including new launches and the development of a novel dual energy platform, while navigating challenges such as market competition, regulatory compliance, and supply chain risks.
2026-02-19 12:26:44
AtriCure (ATRC) posted a Q4 2025 profit with revenue of US$140.5 million and basic EPS of US$0.04, marking a shift from previous losses. Despite this quarterly improvement, the company remains loss-making on a trailing twelve-month basis, with a basic EPS of US$0.24. This mixed financial picture creates tension between bullish forecasts, which predict significant earnings growth and profitability within three years, and a cautious narrative highlighting the current losses, significant insider selling, and a share price far above its discounted cash flow fair value.
2026-02-19 00:12:44
Canaccord Genuity has lowered its price target for AtriCure Inc. (NASDAQ:ATRC) from $64 to $53, while maintaining a Buy rating, due to compression in comparable company multiples. Despite this, the firm highlighted AtriCure's strong Q4 revenue growth, positive adjusted EBITDA, and robust financial health, reiterating its 2026 revenue and EBITDA guidance. The outlook from other analysts is mixed, with Needham reiterating a Buy, Oppenheimer downgrading to Perform, and Citizens maintaining a Market Outperform.
